Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression
NCT00835419
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
P276-00
Sponsor
Piramal Enterprises Limited